Fig. 7: Inhibitor of KLF5 facilitates the cytotoxic effect of oxaliplatin.

A–E PDAC cells were treated with ML264 in the presence or absence of oxaliplatin (Oxa) or gemcitabine (Gem), or nab-paclitaxel (nab-PTX), or 5-FU, or irinotecan (Iri) for 48 h, and cell death was detected by PI labeling. CFPAC-1 and Capan-1 cells were subcutaneously inoculated in nude mice. The mice were divided into NC, ML264, Oxa, and ML264+Oxa groups. F, I Tumor size was measured using vernier calipers (**P < 0.01). G, J Tumor growth curves depicted the tumor volumes. H, K MDA levels of the indicated tumors were detected. L Expression of KLF5 and the proliferation marker Ki-67 were detected in tumor tissue sections from the xenografts using IHC staining (n = 5, scale bar, 50 μm).